Free Metastatic Prostate Cancer Prognosis Calculator

What Is the Metastatic Prostate Cancer Prognosis Calculator?

This online tool offers a statistical estimate of life expectancy and mortality risk for men diagnosed with prostate cancer, with a focus on advanced or metastatic disease. All figures provided are projections based on broad population data; they cannot account for individual variations in disease behavior, treatment response, or personal health history. The results are meant to support discussions with a medical professional, not to replace a physician’s judgment.

Understanding Prostate Cancer and Its Risk Factors

Prostate cancer originates in the prostate gland, a walnut‑sized organ that is part of the male reproductive system. Worldwide, it is the second most common malignancy, with more than 1.2 million new cases diagnosed each year. In the United States, roughly 1 in 9 men will develop prostate cancer during their lifetime. The outlook for many is favorable: over 98% of patients survive at least 10 years after diagnosis.

Key risk factors include:

• Advanced age
• African‑American ethnicity
• Family history of prostate, breast, or ovarian cancer (especially when diagnosed at a young age)
• Obesity (body mass index ≥ 30)
• Cigarette smoking

Diagnosis and the Gleason Score

Screening for prostate cancer in asymptomatic men involves:

• Prostate‑specific antigen (PSA) test: assessment of PSA level and its doubling time.
• Digital rectal examination (DRE): manual palpation of the prostate via the rectum.

When symptoms are present or screening results are suspicious, further evaluation includes:

• Transrectal ultrasound (TRUS): imaging to examine prostate structure.
• Prostate biopsy: tissue sampling to determine the cancer grade using the Gleason score.

The Gleason score—a sum of two grades ranging from 2 to 10—is a central factor in prognosis and is required by the calculator.

Tumor Stages and Long-Term Survival

Prostate cancer progression is classified with the TNM staging system. The table below describes the four major stages and their corresponding 15‑year cancer‑specific survival rates.

Stage	Description	15‑Year Cancer‑Specific Survival
T1	Tumor not palpable or visible; often found incidentally	99%
T2	Tumor confined within the prostate; detectable by DRE or imaging	96%
T3	Tumor extends beyond the prostate or into the seminal vesicles	91%
T4	Tumor invades adjacent organs or lymph nodes	See below

For T1–T3 disease, survival approaches that of the general population; most men with these stages die from causes other than prostate cancer. Stage 4 (any T4, N+, or M1) automatically indicates metastatic spread. The 5‑year survival for metastatic prostate cancer is approximately 31%—meaning only about one‑third of patients live beyond five years after diagnosis.

Average Survival Across All Stages

The pooled survival data for all prostate cancer stages show:

Time Frame	Survival Rate
5 years	Nearly 100%
10 years	Nearly 98%
15 years	Nearly 95%

These high numbers reflect the generally favorable prognosis of early‑stage disease.

How to Use the Prostate Cancer Prognosis Calculator

The calculator requires the following inputs to generate a personalized estimate:

1. Age, weight, and height – used to calculate body mass index (BMI) and age‑related baseline risk.
2. Gleason score – obtained from your biopsy; lower scores correlate with better outcomes.
3. Presence of distant metastases – has the cancer spread beyond the prostate and seminal vesicles? Metastatic disease lowers survival.
4. Overall health status – consider chronic illnesses, past surgeries, and your self‑rated health compared to peers.
5. Smoking status – whether you currently smoke, have smoked in the past, or have never smoked.

The algorithm then combines these details with epidemiological data to estimate life expectancy and mortality risk.

How the Prognosis Is Calculated

The tool’s mathematical model integrates findings from multiple peer‑reviewed studies (Zhang et al. 2015, Huncharek et al. 2010, Albertsen et al. 2005, Preston 2011) along with the U.S. Social Security Actuarial Life Tables. The main modifiers applied to baseline life expectancy are outlined below.

Gleason Score and Mortality

Higher Gleason scores are strongly associated with increased mortality. The table shows mortality rates per 1,000 person‑years for each score category.

Gleason Score	Mortality Rate (per 1,000 person‑years)
2–4	6
5	12
6	30
7	65
8–10	121

Impact of Obesity

Obesity (BMI ≥ 30) shortens life expectancy in the general population by an average of 1.85 years in U.S. adults. Moreover, it raises the risk of aggressive prostate cancer (relative risk RR = 1.14; 95% CI 1.04–1.25) and increases prostate‑cancer‑specific mortality (RR = 1.24; 95% CI 1.15–2.33). BMI is computed as:

$$\text{BMI} = \dfrac{\text{weight (kg)}}{[\text{height (m)}]^{2}}$$

Impact of Smoking

Current smoking elevates the risk of dying from prostate cancer. Compared to never smokers, the relative risk of prostate‑cancer‑specific mortality is 1.14 (95% CI 1.06–1.19). For heavy smokers, this risk can be up to 30% higher.

Important Limitations

This calculator provides statistical estimates only. It is not a diagnostic tool and cannot predict an individual’s actual outcome. All results should be discussed with a qualified healthcare provider before making any treatment decisions.